Cardiac Amyloidosis and the V142I Transthyretin Variant

JAMA Author Interviews
12/05/2024 13 min
Cardiac Amyloidosis and the V142I Transthyretin Variant

Listen "Cardiac Amyloidosis and the V142I Transthyretin Variant"

Descargar episodio Ver en sitio original

Episode Synopsis

What is the natural history and cardiovascular burden of the V142I transthyretin variant among US Black individuals who carry this variant? Senthil Selvaraj, MD, MS, MA, from Duke University, and Scott D. Solomon, MD, from Brigham and Women’s Hospital, discuss this and more with JAMA Executive Editor Gregory Curfman, MD. Related Content: Cardiovascular Burden of the V142I Transthyretin Variant Addressing Health Disparities—The Case for Variant Transthyretin Cardiac Amyloidosis Grows Stronger Heart Failure in African American Individuals, Version 2.0 Cardiac Amyloidosis Due to Transthyretin Protein

More episodes of the podcast JAMA Author Interviews

From the JAMA Network: Acetaminophen Use in Pregnancy and Risk of Autism 30/09/2025
From the JAMA Network: AI-Based Analysis for Parkinsonism 30/08/2025
Treatment of Complicated Staphylococcus aureus Bacteremia 13/08/2025
From the JAMA Network: Incidence and Nature of Antidepressant Discontinuation Symptoms 05/08/2025
From the JAMA Network: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension 28/07/2025
Life Support and Outcomes in Patients Admitted to Intensive Care Units 14/04/2025
Increases in Invasive Group A Streptococcal Infections 07/04/2025
Preventive Health Care Among Adults Eligible for Lung Cancer Screening 02/04/2025
Cardiac Arrests During Long-Distance Running: What’s Changed? 30/03/2025
Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS) 18/03/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA